Share Price:

APNASPENAspen Pharmacare Hldgs21701-219 (-1.00%)

Aspen is in a closed period from 1 January until the publication of our interim results on the JSE SENS platform to be released on 4 March 2024.

Key ARV Products Viread® and Truvada® Registered by MCC

JSE listed Aspen, a leading global manufacturer and distributor of anti-retroviral (ARV) medicines, today announced that it has been granted certification from the Medicines Control Council of South Africa (MCC) to manufacture and distribute the two key ARV products Viread® (tenofovir disoproxil fumarate) and Truvada® (emtricitabine and tenofovir disoproxil fumarate) in the South African market.… Continue reading Key ARV Products Viread® and Truvada® Registered by MCC

Tibotec and Aspen Collaborate on PREZISTA™ access plan for Africa

Co Cork, Ireland (April 4th, 2007) – Tibotec Pharmaceuticals Ltd. has signed a royalty-free, non-exclusive license agreement with Aspen of South Africa. Aspen will register, package and distribute the protease inhibitor PREZISTA™ (darunavir, DRV) in sub-Saharan Africa. Tibotec has selected Aspen because of the company’s extensive African distribution network and pioneering endeavors in enhancing access… Continue reading Tibotec and Aspen Collaborate on PREZISTA™ access plan for Africa

Closed Period

Aspen is in a closed period from 1 January until the publication of our interim results on the JSE SENS platform scheduled to be released on 1 March 2023.

The live presentation will take place in Cape Town at 08h30 on 2 March 2023.